Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Brink, Adrian![]() |
|
dc.contributor.author | Coetzee, Jennifer![]() |
|
dc.contributor.author | Richards, Guy A.![]() |
|
dc.contributor.author | Feldman, Charles![]() |
|
dc.contributor.author | Lowman, Warren![]() |
|
dc.contributor.author | Tootla, Hafsah D.![]() |
|
dc.contributor.author | Miller, Malcolm G.A.![]() |
|
dc.contributor.author | Niehaus, Abraham J.![]() |
|
dc.contributor.author | Wasserman, Sean![]() |
|
dc.contributor.author | Perovic, Olga![]() |
|
dc.contributor.author | Govind, Chetna N.![]() |
|
dc.contributor.author | Schellack, Natalie![]() |
|
dc.contributor.author | Mendelson, Marc![]() |
|
dc.date.accessioned | 2023-02-27T09:28:40Z | |
dc.date.available | 2023-02-27T09:28:40Z | |
dc.date.issued | 2022-10-20 | |
dc.description.abstract | Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidimeavibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa’s multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term. | en_US |
dc.description.department | Pharmacology | en_US |
dc.description.librarian | am2023 | en_US |
dc.description.uri | http://www.sajid.co.za | en_US |
dc.identifier.citation | Brink, A.J., Coetzee, J., Richards, G.A., et al. Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa. Southern African Journal of Infectious Diseases 2022; 37(1), a453. https://DOI.org/10.4102/sajid.v37i1.453. | en_US |
dc.identifier.issn | 2312-0053 (print) | |
dc.identifier.issn | 2313-1810 (online) | |
dc.identifier.other | 10.4102/sajid.v37i1.453 | |
dc.identifier.uri | https://repository.up.ac.za/handle/2263/89842 | |
dc.language.iso | en | en_US |
dc.publisher | AOSIS | en_US |
dc.rights | © 2022. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License. | en_US |
dc.subject | Antimicrobial stewardship | en_US |
dc.subject | β-Lactamase inhibitor combinations | en_US |
dc.subject | Ceftazidimeavibactam | en_US |
dc.subject | Ceftolozane-tazobactam | en_US |
dc.subject | Gram-negatives | en_US |
dc.subject | Pseudomonas aeruginosa | en_US |
dc.subject | Enterobacterales | en_US |
dc.subject | Beta-lactam (β-Lactam) | en_US |
dc.subject | Beta-lactamase (β-Lactam) | en_US |
dc.subject | Difficult-to-treat resistant (DTR) | en_US |
dc.title | Best practices : appropriate use of the new β-lactam/ β-lactamase inhibitor combinations, ceftazidimeavibactam and ceftolozane-tazobactam in South Africa | en_US |
dc.type | Article | en_US |